ZA200509063B - Impiantable polymeric device for sustained release of nalmefene - Google Patents
Impiantable polymeric device for sustained release of nalmefene Download PDFInfo
- Publication number
- ZA200509063B ZA200509063B ZA200509063A ZA200509063A ZA200509063B ZA 200509063 B ZA200509063 B ZA 200509063B ZA 200509063 A ZA200509063 A ZA 200509063A ZA 200509063 A ZA200509063 A ZA 200509063A ZA 200509063 B ZA200509063 B ZA 200509063B
- Authority
- ZA
- South Africa
- Prior art keywords
- nalmefene
- implantable device
- implantable
- eva
- devices
- Prior art date
Links
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 title claims description 181
- 229960005297 nalmefene Drugs 0.000 title claims description 179
- 238000013268 sustained release Methods 0.000 title description 13
- 239000012730 sustained-release form Substances 0.000 title description 13
- 238000000034 method Methods 0.000 claims description 51
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 50
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 50
- 238000011282 treatment Methods 0.000 claims description 39
- 208000007848 Alcoholism Diseases 0.000 claims description 31
- 201000007930 alcohol dependence Diseases 0.000 claims description 30
- 239000011159 matrix material Substances 0.000 claims description 30
- 230000036470 plasma concentration Effects 0.000 claims description 21
- 238000001727 in vivo Methods 0.000 claims description 20
- 241000124008 Mammalia Species 0.000 claims description 14
- 206010057852 Nicotine dependence Diseases 0.000 claims description 14
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 14
- 230000004888 barrier function Effects 0.000 claims description 12
- 238000001125 extrusion Methods 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 11
- 230000002459 sustained effect Effects 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 9
- 239000011148 porous material Substances 0.000 claims description 8
- 210000001015 abdomen Anatomy 0.000 claims description 3
- 239000007943 implant Substances 0.000 description 63
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 239000011248 coating agent Substances 0.000 description 17
- 238000000576 coating method Methods 0.000 description 17
- 238000002513 implantation Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000035622 drinking Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 11
- -1 poly(vinyl alcohol) Polymers 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- GYWMRGWFQPSQLK-OPHZJPRHSA-N (4r,4as,7as,12bs)-3-(cyclopropylmethyl)-7-methylidene-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol;hydron;chloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 GYWMRGWFQPSQLK-OPHZJPRHSA-N 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 229960003086 naltrexone Drugs 0.000 description 8
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 229960000677 nalmefene hydrochloride Drugs 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000007607 die coating method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000001050 pharmacotherapy Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 208000001613 Gambling Diseases 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010034158 Pathological gambling Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 229920013641 bioerodible polymer Polymers 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000019788 craving Nutrition 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100001079 no serious adverse effect Toxicity 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 238000001671 psychotherapy Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000012488 Opiate Overdose Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 238000009225 cognitive behavioral therapy Methods 0.000 description 1
- 238000009226 cognitive therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960002563 disulfiram Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009231 family therapy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000005032 impulse control Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002285 poly(styrene-co-acrylonitrile) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229940116238 revex Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000000807 solvent casting Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229920011532 unplasticized polyvinyl chloride Polymers 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47491603P | 2003-05-30 | 2003-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200509063B true ZA200509063B (en) | 2007-03-28 |
Family
ID=33551514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200509063A ZA200509063B (en) | 2003-05-30 | 2004-05-27 | Impiantable polymeric device for sustained release of nalmefene |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20050031668A1 (ja) |
| EP (1) | EP1638536A2 (ja) |
| JP (1) | JP2007502866A (ja) |
| AU (1) | AU2004247057A1 (ja) |
| CA (1) | CA2526101A1 (ja) |
| MX (1) | MXPA05012768A (ja) |
| WO (1) | WO2004110400A2 (ja) |
| ZA (1) | ZA200509063B (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| EP2561860B1 (en) * | 2002-05-31 | 2018-02-28 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine |
| MXPA05010450A (es) * | 2003-03-31 | 2005-11-04 | Titan Pharmaceuticals Inc | Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina. |
| ES2432556T3 (es) | 2004-08-04 | 2013-12-04 | Evonik Corporation | Métodos para fabricar dispositivos de suministro y sus dispositivos |
| US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| US20110091518A1 (en) * | 2009-09-22 | 2011-04-21 | Danielle Biggs | Implant devices having varying bioactive agent loading configurations |
| AU2011227289B2 (en) | 2010-03-16 | 2016-01-21 | Titan Pharmaceuticals, Inc. | Heterogeneous implantable devices for drug delivery |
| WO2017196697A1 (en) * | 2016-05-12 | 2017-11-16 | Merck Sharp & Dohme Corp. | Drug delivery system for the delivery of antiviral agents |
| CN110022794A (zh) * | 2016-10-05 | 2019-07-16 | 泰坦医药品公司 | 具有减少的突释的用于药物递送的可植入装置 |
| CN111971026A (zh) | 2018-05-24 | 2020-11-20 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| EP3801378A4 (en) | 2018-05-24 | 2022-02-23 | Celanese EVA Performance Polymers LLC | IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND |
| CN109200017B (zh) * | 2018-11-22 | 2021-03-02 | 辽宁海思科制药有限公司 | 一种盐酸纳美芬注射液药物组合物及其制备方法 |
| CN114206336A (zh) * | 2019-08-13 | 2022-03-18 | 默沙东公司 | 用于递送抗病毒剂的药物递送系统 |
| BR102020025389A2 (pt) * | 2020-12-11 | 2022-06-21 | Edson Luiz Peracchi | Implante subcutâneo reabsorvível de longa duração com liberação prolongada de substância farmacologicamente ativa pré-concentrada em polímero para tratamento da dependência a nicotina e processo |
| CA3215040A1 (en) * | 2021-04-20 | 2022-10-27 | Oakwood Laboratories, Llc | Microsphere formulations comprising nalmefene and methods for making and using the same |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4069307A (en) * | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
| US4351337A (en) * | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
| US4148871A (en) * | 1977-10-11 | 1979-04-10 | Pitt Colin G | Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers |
| US4898733A (en) * | 1985-11-04 | 1990-02-06 | International Minerals & Chemical Corp. | Layered, compression molded device for the sustained release of a beneficial agent |
| US4692451A (en) * | 1985-12-11 | 1987-09-08 | Trustees Of Tufts College | Method for preventing stereotypic behavior in animals |
| US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| US5114719A (en) * | 1987-04-29 | 1992-05-19 | Sabel Bernhard A | Extended drug delivery of small, water-soluble molecules |
| US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| US5601835A (en) * | 1987-04-29 | 1997-02-11 | Massachusetts Institute Of Technology | Polymeric device for controlled drug delivery to the CNS |
| DE19975054I2 (de) * | 1987-08-08 | 2000-04-13 | Akzo Nobel Nv | Kontrazeptives Implantat |
| US5156844A (en) * | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
| US4882335A (en) * | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| DE69001672T2 (de) * | 1989-06-21 | 1993-12-23 | Univ Brown Res Found | Neurologisches therapiesystem. |
| US5219858A (en) * | 1990-03-27 | 1993-06-15 | Parnell Pharmaceuticals, Inc. | Method and compositions for effecting withdrawal from drug dependency |
| US5114718A (en) * | 1990-09-20 | 1992-05-19 | The Procter & Gamble Company | Sustained release compositions for treating periodontol disease |
| US5086085A (en) * | 1991-04-11 | 1992-02-04 | The United States Of America As Represented By The Department Of Energy | Melamine-formaldehyde aerogels |
| US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| FR2695826B1 (fr) * | 1992-09-21 | 1995-01-06 | Theramex | Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention. |
| JP3720386B2 (ja) * | 1993-12-27 | 2005-11-24 | 住友製薬株式会社 | 薬物放出制御製剤 |
| US5633000A (en) * | 1994-06-23 | 1997-05-27 | Axxia Technologies | Subcutaneous implant |
| AU4975996A (en) * | 1995-02-10 | 1996-08-27 | Matthew A Bergan | Method and device for administering analgesics |
| US5877224A (en) * | 1995-07-28 | 1999-03-02 | Rutgers, The State University Of New Jersey | Polymeric drug formulations |
| US6004962A (en) * | 1995-09-11 | 1999-12-21 | Gooberman; Lance L. | Rapid opioid detoxification |
| US5733565A (en) * | 1996-02-23 | 1998-03-31 | The Population Council, Center For Biomedical Research | Male contraceptive implant |
| US20040024006A1 (en) * | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
| US6271240B1 (en) * | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
| US20030211157A1 (en) * | 1996-05-06 | 2003-11-13 | Simon David Lew | Semi-sol delivery blend for water soluble molecules |
| US6203813B1 (en) * | 1997-01-13 | 2001-03-20 | Lance L. Gooberman | Pharmaceutical delivery device and method of preparation therefor |
| US20010036469A1 (en) * | 1997-01-13 | 2001-11-01 | Gooberman Lance L. | Opiate antagonist implant and process for preparation therefor |
| TW460599B (en) * | 1998-01-14 | 2001-10-21 | Toshiba Corp | Method for forming fine wiring pattern |
| AU2981099A (en) * | 1998-03-09 | 1999-09-27 | Trustees Of Tufts College | Treatment of compulsive behaviours in man and animals |
| EP0945133A1 (en) * | 1998-03-26 | 1999-09-29 | Lipha | Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator |
| CN1434704A (zh) * | 1999-12-16 | 2003-08-06 | 三叉技术有限责任公司 | 延长其受体负荷剂量的治疗剂释放的系统和方法 |
| CA2444894C (en) * | 2001-04-26 | 2013-06-25 | Control Delivery Systems, Inc. | Sustained release drug delivery system containing codrugs |
| US20020198574A1 (en) * | 2001-06-22 | 2002-12-26 | Ron Gumpert | Automatic sobriety training and reconditioning system |
| US20030170286A1 (en) * | 2001-12-10 | 2003-09-11 | Paul Ashton | Treatment of genitourinary tract disorders |
| EP2561860B1 (en) * | 2002-05-31 | 2018-02-28 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine |
| MXPA05010450A (es) * | 2003-03-31 | 2005-11-04 | Titan Pharmaceuticals Inc | Dispositivo polimerico implantable para la liberacion prolongada de agonistas de dopamina. |
| US20050245541A1 (en) * | 2004-03-19 | 2005-11-03 | Elliot Ehrich | Methods for treating alcoholism |
| WO2007139744A2 (en) * | 2006-05-23 | 2007-12-06 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of buprenorphine with minimal initial burst |
-
2004
- 2004-05-27 AU AU2004247057A patent/AU2004247057A1/en not_active Abandoned
- 2004-05-27 ZA ZA200509063A patent/ZA200509063B/en unknown
- 2004-05-27 WO PCT/US2004/016944 patent/WO2004110400A2/en active Application Filing
- 2004-05-27 MX MXPA05012768A patent/MXPA05012768A/es not_active Application Discontinuation
- 2004-05-27 CA CA002526101A patent/CA2526101A1/en not_active Abandoned
- 2004-05-27 JP JP2006533496A patent/JP2007502866A/ja active Pending
- 2004-05-27 EP EP04753725A patent/EP1638536A2/en not_active Withdrawn
- 2004-05-27 US US10/856,178 patent/US20050031668A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004110400A3 (en) | 2005-02-17 |
| EP1638536A2 (en) | 2006-03-29 |
| US20050031668A1 (en) | 2005-02-10 |
| MXPA05012768A (es) | 2006-02-22 |
| CA2526101A1 (en) | 2004-12-23 |
| AU2004247057A1 (en) | 2004-12-23 |
| WO2004110400A2 (en) | 2004-12-23 |
| JP2007502866A (ja) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220241186A1 (en) | Implantable polymeric device for sustained release of buprenorphine | |
| AU711323B2 (en) | Subcutaneous implant | |
| EP1610791B1 (en) | Implantable polymeric device for sustained release of dopamine agonist | |
| US20050031668A1 (en) | Implantable polymeric device for sustained release of nalmefene | |
| AU2004228017B2 (en) | Implantable polymeric device for sustained release of dopamine agonist | |
| US20070275031A1 (en) | Implantable polymeric device for sustained release of buprenorphine with minimal initial burst | |
| EP3340968B1 (en) | Implantable naltrexone tablets | |
| Costantini et al. | Implantable technology for long-term delivery of nalmefene for treatment of alcoholism | |
| US5891456A (en) | Glyceryl monosterate based biodegradable implants for site-specific delivery of drugs |